Company Profile
Clene Inc. Stock Price, News & Catalysts
- Ticker:
- CLNN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.15 USD (+7.51%)
Close
Last updated: September 17, 2026
75M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, CLNN closed up 7.51% at $4.15. No new same-company headline was identified in the current news window.
Company overview
Neurodegenerative-Disease Nanomedicine
Clene is a late clinical-stage biopharmaceutical company developing nanotechnology-based therapies intended to improve mitochondrial health and preserve neuronal function. Its programs target neurodegenerative diseases including amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson's disease.
CNM-Au8
CNM-Au8 is an oral suspension of catalytically active gold nanocrystals designed to increase cellular energy production and utilization. The candidate targets mitochondrial function and the NAD pathway while reducing oxidative stress, with the goal of improving neuronal resilience, neuroprotection, and remyelination.
ALS Regulatory Program
Clene is prioritizing CNM-Au8 for ALS and plans to seek accelerated approval using neurofilament light as a surrogate biomarker. The planned NDA will integrate biomarker and clinical evidence from the Phase 2 HEALEY ALS Platform Trial, its open-label extension, the Phase 2 RESCUE-ALS study, and an NIH-sponsored expanded-access protocol.
Future catalysts
- Submission of the CNM-Au8 NDA for ALS under the accelerated approval pathway in early fourth-quarter 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Clene Inc. (CLNN)?
Clene Inc. (CLNN) most recently closed at 4.15 USD, a +7.51% move versus the previous session.
What is the market cap of Clene Inc. (CLNN)?
Clene Inc. currently has a market capitalization of 75M USD on BioPharmSignal.
What does Clene Inc. do?
Neurodegenerative-Disease Nanomedicine Clene is a late clinical-stage biopharmaceutical company developing nanotechnology-based therapies intended to improve mitochondrial health and preserve neuronal function. Its programs target neurodegenerative diseases including amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson's disease. CNM-Au8 CNM-Au8...
On which exchange is CLNN stock listed?
Clene Inc. (CLNN) is associated with NASDAQ, United States, Biopharma.
What is RESCUE-ALS?
The planned NDA will integrate biomarker and clinical evidence from the Phase 2 HEALEY ALS Platform Trial, its open-label extension, the Phase 2 RESCUE-ALS study, and an NIH-sponsored expanded-access protocol.
Which conditions is Clene Inc. targeting with RESCUE-ALS?
Neurodegenerative-Disease Nanomedicine Clene is a late clinical-stage biopharmaceutical company developing nanotechnology-based therapies intended to improve mitochondrial health and preserve neuronal function. Its programs target neurodegenerative diseases including amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson's disease. CNM-Au8 CNM-Au8...
How does Clene Inc. describe recent progress with RESCUE-ALS?
Submission of the CNM-Au8 NDA for ALS under the accelerated approval pathway in early fourth-quarter 2026.
What is Neurodegenerative-Disease?
Neurodegenerative-Disease Nanomedicine Clene is a late clinical-stage biopharmaceutical company developing nanotechnology-based therapies intended to improve mitochondrial health and preserve neuronal function.